Effect of pravastatin on low-density lipoprotein oxidation and myocardial perfusion in young adults with type 1 diabetes

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 24, Issue 7, 2004, Pages 1303-1308

  Janatuinen, Tuula ^a   Knuuti, Juhani ^a   Toikka, Jyri O ^a   Ahotupa, Markku ^a   Nuutila, Pirjo ^a   Rönnemaa, Tapani ^a   Raitakari, Olli T ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Diene conjugation; LDL oxidation; Myocardial perfusion; Positron emission tomography; Pravastatin

Indexed keywords

DIPYRIDAMOLE; LOW DENSITY LIPOPROTEIN; PLACEBO; PRAVASTATIN; STATINE DERIVATIVE;

ADULT; ARTICLE; BLOOD VESSEL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEART MUSCLE PERFUSION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERINSULINEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; MALE; OXIDATIVE STRESS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; CORONARY CIRCULATION; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DIPYRIDAMOLE; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE CLAMP TECHNIQUE; HEART; HEMODYNAMIC PROCESSES; HUMANS; HYPERINSULINISM; LIPOPROTEINS, LDL; MALE; OXIDATION-REDUCTION; POSITRON-EMISSION TOMOGRAPHY; PRAVASTATIN; RETINAL VESSELS;

EID: 3042854199     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000132409.87124.60     Document Type: Article

References (38)

1. Lloyd CE, Kuller LH, Ellis D, Becker DJ, Wing RR, Orchard TJ. Coronary artery disease in IDDM. Gender differences in risk factors but not risk. Arterioscler Thromb Vasc Biol. 1996;16:720-726.
2. Clarkson P, Celermajer DS, Donald AE, Sampson M, Sorensen KE, Adams M, Yue DK, Betteridge DJ, Deanfield JE. Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. J Am Coll Cardiol. 1996;28:573-579.
3. Lekakis J, Papamichael C, Anastasiou H, Alevizaki M, Desses N, Souvatzoglou A, Stamatelopoulos S, Koutras DA. Endothelial dysfunction of conduit arteries in insulin-dependent diabetes mellitus without microalbuminuria. Cardiovasc Res. 1997;34:164-168.
4. Pitkänen OP, Nuutila P, Raitakari OT, Rönnemaa T, Koskinen PJ, Iida H, Lehtimäki TJ, Laine HK, Takala T, Viikari JS, Knuuti J. Coronary flow reserve is reduced in young men with IDDM. Diabetes. 1998;47: 248-254.
5. Sundell J, Laine H, Nuutila P, Rönnemaa T, Luotolahti M, Raitakari O, Knuuti J. The effects of insulin and short term hyperglycaemia on myocardial blood flow in young men with uncomplicated type I diabetes. Diabetologia. 2002;45:775-782.
6. Cominacini L, Garbin U, Pastorino AM, Fratta PA, Campagnola M, De Santis A, Davoli A, Lo Cascio V. Increased susceptibility of LDL to in vitro oxidation in patients with insulin-dependent and non-insulin-dependent diabetes mellitus. Diabetes Res. 1994;26:173-184.
7. Festa A, Kopp HP, Schernthaner G, Menzel EJ. Autoantibodies to oxidised low density lipoproteins in IDDM are inversely related to metabolic control and microvascular complications. Diabetologia. 1998;41:350-356.
8. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915-924.
9. Liao JK, Shin WS, Lee WY, Clark SL. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem. 1995;270:319-324.
10. Raitakari OT, Pitkänen OP, Lehtimäki T, Lahdenperä S, Iida H, Ylä-Herttuala S, Luoma J, Mattila K, Nikkari T, Taskinen MR, Viikari JS, Knuuti J. In vivo low density lipoprotein oxidation relates to coronary reactivity in young men. J Am Coll Cardiol. 1997;30:97-102.
11. Hoffman R, Brook GJ, Aviram M. Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies. Atherosclerosis. 1992;93:105-113.
12. Chen MF, Hsu HC, Lee YT. Short-term treatment with low-dose pravastatin attenuates oxidative susceptibility of low-density lipoprotein in hypercholesterolemic patients. Cardiovasc Drugs Ther. 1997;11:787-793.
13. Kleinveld HA, Demacker PN, De Haan AF, Stalenhoef AF. Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors. Eur J Clin Invest. 1993;23:289-295.
14. Harada N, Kashiwagi A, Nishio Y, Kikkawa R. Effects of cholesterol-lowering treatments on oxidative modification of plasma intermediate density lipoprotein plus low density lipoprotein fraction in Type 2 diabetic patients. Diabetes Res Clin Pract. 1999;43:111-120.
15. Zhang A, Vertommen J, Van Gaal L, De LI. Effects of pravastatin on lipid levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients. Diabetes Res Clin Pract. 1995;29:189-194.
16. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103:357-362.
17. Jula A, Marniemi J, Huupponen R, Virtanen A, Rastas M, Rönnemaa T. Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial. JAMA. 2002; 287:598-605.
18. Vasankari T, Ahotupa M, Toikka J, Mikkola J, Irjala K, Pasanen P, Neuvonen K, Raitakari O, Viikari J. Oxidized LDL and thickness of carotid intima-media are associated with coronary atherosclerosis in middle-aged men: lower levels of oxidized LDL with statin therapy. Atherosclerosis. 2001;155:403-412.
19. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
20. Sipilä H., Clark JC, Peltola O, Teräs M. An automatic (O-15)H2O production system for heart and brain studies. J Labelled Cpd Radiopharm. 2001;44:S1066-S1068.
21. Alenius S, Ruotsalainen U. Bayesian image reconstruction for emission tomography based on median root prior. Eur J Nucl Med. 1997;24:258-265.
22. Iida H, Rhodes CG, de Silva R, Araujo LI, Bloomfield PM, Lammertsma AA, Jones T. Use of the left ventricular time-activity curve as a noninvasive input function in dynamic oxygen-15-water positron emission tomography. J Nucl Med. 1992;33:1669-1677.
23. Iida H, Kanno I, Takahashi A, Miura S, Murakami M, Takahashi K, Ono Y, Shishido F, Inugami A, Tomura N. Measurement of absolute myocardial blood flow with H215O and dynamic positron-emission tomography. Strategy for quantification in relation to the partial-volume effect. Circulation. 1988;78:104-115.
24. Kappus H. Lipid peroxidation: mechanisms, analysis, enzymology and biological relevance. In: Sies H, ed. Oxidative stress. London: Academic Press; 1985:273-310.
25. Cosentino F, Hishikawa K, Katusic ZS, Luscher TF. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation. 1997;96:25-28.
26. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest. 1993;91:2546-2551.
27. Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol. 2000;20:61-69.
28. Chen HC, Guh JY, Shin SJ, Lai YH. Pravastatin suppress superoxide and fibronectin production of glomerular mesangial cells induced by oxidized-LDL and high glucose. Atherosclerosis. 2002;160:141-146.
29. Pietzsch J, Lattke P, Julius U. Oxidation of apolipoprotein B-100 in circulating LDL is related to LDL residence time. In vivo insights from stable-isotope studies. Arterioscler Thromb Vasc Biol. 2000;20:E63-E67.
30. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997;95:1126-1131.
31. Sheu WH, Juang BL, Chen YT, Lee WJ. Endothelial dysfunction is not reversed by simvastatin treatment in type 2 diabetic patients with hypercholesterolemia. Diabetes Care. 1999;22:1224-1225.
32. van Venrooij FV, van de Ree MA, Bots ML, Stolk RP, Huisman MV, Banga JD. Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial. Diabetes Care. 2002;25:1211-1216.
33. Mullen MJ, Wright D, Donald AE, Thorne S, Thomson H, Deanfield JE. Atorvastatin but not L-arginine improves endothelial function in type I diabetes mellitus: a double-blind study. J Am Coll Cardiol. 2000;36:410-416.
34. Bergmann SR, Herrero P, Markham J, Weinheimer CJ, Walsh MN. Noninvasive quantitation of myocardial blood flow in human subjects with oxygen-15-labeled water and positron emission tomography. J Am Coll Cardiol. 1989;14:639-652.
35. Nitzsche EU, Choi Y, Czernin J, Hoh CK, Huang SC, Schelbert HR. Noninvasive quantification of myocardial blood flow in humans. A direct comparison of the [13N]ammonia and the [150]water techniques. Circulation. 1996;93:2000-2006.
36. Rubanyi GM, Romero JC, Vanhoutte PM. Flow-induced release of endothelium-derived relaxing factor. Am J Physiol. 1986;250: H1145-H1149.
37. Buus NH, Böttcher M, Hermansen F, Sander M, Nielsen TT, Mulvany MJ. Influence of nitric oxide synthase and adrenergic inhibition on adenosine-induced myocardial hyperemia. Circulation. 2001;104:2305-2310.
38. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44:S14-S21.